Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T95241
(Former ID: TTDNR00751)
|
|||||
| Target Name |
Calcium-activated potassium channel KCa2 (KCNN)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 3 Target-related Diseases | + | ||||
| 1 | Ataxic disorder [ICD-11: 8A03] | |||||
| 2 | Supraventricular tachyarrhythmia [ICD-11: BC81] | |||||
| 3 | Tremor-related disorder [ICD-11: 8A04] | |||||
| Function |
Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to the slow component of synaptic afterhyperpolarization. The channel is blockedby apamin.
Click to Show/Hide
|
|||||
| BioChemical Class |
Voltage-gated ion channel
|
|||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 3 Clinical Trial Drugs | + | ||||
| 1 | AP-30663 | Drug Info | Phase 1/2 | Atrial fibrillation | [1] | |
| 2 | CAD-1883 | Drug Info | Phase 1/2 | Ataxic disorder | [1] | |
| 3 | CAD-1833 | Drug Info | Phase 1 | Essential tremor or related tremors | [2] | |
| Mode of Action | [+] 3 Modes of Action | + | ||||
| Inhibitor | [+] 1 Inhibitor drugs | + | ||||
| 1 | AP-30663 | Drug Info | [1] | |||
| Activator | [+] 1 Activator drugs | + | ||||
| 1 | CAD-1883 | Drug Info | [1] | |||
| Modulator | [+] 1 Modulator drugs | + | ||||
| 1 | CAD-1833 | Drug Info | [2] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.